The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
Abstract Effective drugs are needed for lung cancer, as this disease remains the leading cause of cancer-related deaths. Rexinoids are promising drug candidates for cancer therapy because of their ability to modulate genes involved in inflammation, cell proliferation or differentiation, and apoptosi...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-12-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-020-79260-8 |